Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Boston Scientific Corp announces FDA approval of innovative new defibrillators and heart failure devices


Tuesday, 15 Apr 2014 04:45pm EDT 

Boston Scientific Corp:Receives FDA approval for latest generation of defibrillators and heart failure devices designed to advance patient care.Newly approved devices include DYNAGEN MINI and INOGEN MINI ICDs, as well as the DYNAGEN X4 and INOGEN X4 CRT-Ds.X4 line of quadripolar CRT-Ds offers 70 percent more pacing options to address high capture thresholds and phrenic nerve stimulation effectively, along with largest battery capacity in industry.These newly approved devices continue Boston Scientific history of industry-leading projected longevity and six-year CRT-D warranty. 

Company Quote

13.15
-0.11 -0.83%
19 Dec 2014